S. 1361: Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011

Before you vote › Federal bills

S. 1361: Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011

112th Congress · introduced 2011-07-13 · Health · Latest: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

federal

Save to my notebook What does this mean? Print

Official title

Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011

Plain summary

Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 - Requires the Director of the National Institute of Environmental Health Sciences, as part of the National Toxicology Program, to: (1) establish and implement a research program designed to strengthen the scientific basis of information used by federal agencies to understand the effects of, and reduce human exposure to, endocrine-disrupting chemicals; (2) establish an Endocrine Disruption Expert Panel to report to the Director on issues related to identification, classification, or evaluation of endocrine-disrupting chemicals; (3) for each chemical determined by the Director to be a potential or actual endocrine-disrupting chemical, identify the level of evidence that such chemical is or may be an endocrine-disrupting chemical, the level of concern that such chemical may disrupt the human endocrine system, and the pathways of exposure to the chemical for humans and animals; and (4) provide to Congress and each relevant federal agency and make publicly available every two years an up-to-date list of potential or actual endocrine-disrupting chemicals and a report on the Program's activities and on federal agencies' activities with respect to endocrine-disrupting chemicals. Requires the Panel to: (1) report to the Director on issues related to identification, classification, or evaluation of not more than 10 endocrine-disrupting chemicals or groups of chemicals; (2) evaluate existing research aimed at understanding the biological pathways in humans by which such chemicals operate and identify future research priorities; and (3) maintain a list that identifies chemicals of concern for endocrine disruption effects. Authorizes any federal agency, state, local or tribal government, or person to petition the Director to: (1) determine whether a chemical should be identified by the Program as a potential or actual endocrine-disrupting chemical and included in the list; or (2) reclassify a chemical, revise a finding, or amend any other determination of the Program based upon new information. Provides that a listing, finding, or other determination shall not be subject to judicial review or to correction under the Information Quality Act. Amends the Public Health Service Act to require the Director to conduct and support an Endocrine Disruption Research Program. Authorizes the Director to conduct workshops and forums and provide information on the health effects associated with chemicals that may disrupt the endocrine system. Requires each federal agency with regulatory authority over any chemical included on the list to prepare and publish a written response to each biennial list. Specifies actions each such agency must take if: (1) the Director determines there is a minimal level of concern that a chemical may disrupt the human endocrine system (e.g, developing a strategy for reducing human exposure to the chemical, including methods to promote voluntary actions by industry for reducing such exposure), and (2) the Director finds there is a high level of concern (e.g., prohibiting the use of the chemical in a manner in or affecting interstate commerce unless the pathway to human exposure is mitigated before or in conjunction with such use). Provides for citizen suits to restrain the prohibited use of chemicals under this Act. Requires: (1) the Administrator of the Environmental Protection Agency (EPA) to include findings and determinations of the Program in the Aggregated Computational Toxicology Resource databases to the extent permitted by law, and (2) the Director to establish a program to support graduate and postdoctoral training in fields related to the study and prevention of endocrine disruption.

Congressional Research Service summary (Introduced in Senate), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Sen. Kerry, John F. [D-MA] · 1 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

• Congressional Research Service summary (Introduced in Senate)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-112s1361.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/112/s>

Record fed-us-cong112-s1361 · catalog fed-us-congress-bills-cong112 · updated 2026-11-15 by psicol fed-bills-cong112